Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605183 | 0.88 | ALDH1A1 (1.00) | NPC1ALDH1A1POLBLMNAPABPC1 | |
| SCHEMBL12106 | 0.85 | NPC1 (0.73) | NPC1ALDH1A1POLBLMNAPABPC1 | |
| SCHEMBL18516792 | 0.82 | NPC1 (0.69) | NPC1ALDH1A1POLBLMNAGAA | |
| SCHEMBL21538079 | 0.82 | NPC1 (0.69) | NPC1ALDH1A1LMNAGAAHTT | |
| SCHEMBL14198866 | 0.77 | LMNA (0.68) | NPC1ALDH1A1POLBLMNATP53 | |
| SCHEMBL4930270 | 0.72 | SMN1; SMN2 (0.59) | NPC1ALDH1A1LMNAHTT | |
| SCHEMBL30926439 | 0.70 | PKM (0.81) | NPC1ALDH1A1POLBLMNA | |
| SCHEMBL27180624 | 0.70 | PKM (0.81) | NPC1ALDH1A1POLBLMNA | |
| SCHEMBL10008213 | 0.70 | KMT2A (0.70) | NPC1ALDH1A1POLB | |
| SCHEMBL12274 | 0.70 | POLB (0.62) | NPC1ALDH1A1POLBLMNAPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2020-09-10 | — | — | US | disclosed |
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3561077-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2019-09-12 | — | — | US | disclosed |
| EP-2406389-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9434979-B2 | Methods and compositions for cell-proliferation-related disorders | SERVIER PHARMACEUTICALS LLC | 2016-09-06 | — | — | US | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140187435-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130288284-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2011050210-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010105243-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | MKI67, IDH1, IDH3A | NPC1 2312/4885ALDH1A1 489/4885POLB 273/4885 |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | MKI67, BRCA1, CLN6 | NPC1 808/4885ALDH1A1 2917/4885POLB 60/4885 |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | NPC1 808/4885ALDH1A1 2917/4885POLB 60/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | NPC1 808/4885ALDH1A1 2917/4885POLB 60/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | NPC1 808/4885ALDH1A1 2917/4885POLB 60/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | NPC1 3912/4885ALDH1A1 2900/4885POLB 119/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | NPC1 927/4885ALDH1A1 2219/4885POLB 356/4885 |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | NPC1 808/4885ALDH1A1 2917/4885POLB 60/4885 |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, IDH3B | NPC1 1796/4885ALDH1A1 1582/4885POLB 138/4885 |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | IDH2, IDH1, IDH3A | NPC1 1385/4885ALDH1A1 1072/4885POLB 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.